SSDC+Consortium+Agreement+2025_FNAL+-+signed.pdf

Delaware, Iowa. Kentucky, Maine. Mississippi. North Dakota. Ohio. Oklahoma. Oregon.

Pennsylvania. South Dakota, Utah. Vermont. West Virginia. Wyoming Web Page: www.rxssdc.org Email: ssdc@outlook.com

SOVEREIGN STATES DRUG CONSORTIUM (SSDC)

CONSORTIUM AGREEMENT

This Consortium Agreement (the “Agreement”) is entered into by and between State entities responsible for Medicaid administration, whose representatives have signed below, hereinafter collectively referred to as the “Member States”. When acting as a collaborative group, such group is known as the “Sovereign States Drug Consortium” (SSDC).

The SSDC uses a multi-state administered collaboration to create a purchasing pool to obtain drugs and products for beneficiaries in their Medicaid programs at a lower cost. The pool primarily focuses on negotiating and acquiring rebates supplemental to federal Medicaid rebates from drug manufacturers.

At the same time, the SSDC preserves each State’s ability to manage its pharmacy benefit by customizing its own Preferred Drug List and Prior Approval programs.

The term “membership” is defined as participation in the SSDC for the purpose of obtaining drug rebates. The term “rebate calendar year” is defined as the calendar year of program drug utilization for which rebates can be billed. The term “enroll” is defined as the act of agreeing to the SSDC Agreement for a specific rebate calendar year in order to become an enrolled Member State (hereinafter called “Member State”). Participation in the Agreement is evidenced by the execution of a state-specific Agreement signature page for the year.

As a Medicaid initiative, all SSDC member states are required to obtain approval of their Supplemental Rebate Agreements (SRA) from the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS) through individual Medicaid State Plan Amendments. All member states have received State Plan approval letters from CMS which are available on the CMS website https://www.medicaid.gov/state-resource-center/medicaid-state-plan-amendments/index.html.

Other states may become members of the SSDC by two-thirds vote of the currently enrolled States. A state newly enrolled during an Agreement year may not be specifically listed in the Agreement in the year of enrollment but can be identified by its participation in the Agreement as evidenced by the execution of its Agreement signature page for the year.

For voting purposes, each Member State has only one vote. When calculating two-thirds of a unit for “valid vote” purposes here or elsewhere in this Agreement, any fractional number is rounded up to the

Sovereign States Drug Consortium http://www.rxssdc.org/ mailto:ssdc@outlook.com https://www.medicaid.gov/state-resource-center/medicaid-state-plan-amendments/index.html

SSDC Consortium Agreement 2025 November 14, 2024. Page 2 next whole number. When calculating a majority vote here or elsewhere in this Agreement, the percentage must be more than fifty percent (50%).

A state’s full membership is contingent upon the two-thirds vote of the currently enrolled States, its participation in this Agreement, and CMS approval of its Medicaid State Plan Amendment.

I. Purpose

The purpose of this Agreement is to define conditions under which the Member States agree to coordinate activities related to the operation and management of the SSDC. Upon the agreement by at least two-thirds of the Member States, this Agreement replaces in its entirety all prior Agreements and MOUs that established or operated the SSDC.

Any state that has not executed this Agreement or any Member State that has executed this

Agreement but that has been found in violation of the Agreement and/or is operating in a manner that is contrary to one or more duly executed votes as specified by the Agreement may only participate in the SSDC for the Agreement rebate calendar year to the degree determined by at least two-thirds of the Member States that have executed this Agreement. Any such limited participation shall be dependent upon the continued agreement of at least two-thirds of the fully participating Member States that have executed this Agreement. Any such limited participation may end at any time upon the subsequent determination of at least two-thirds of the fully participating Member States that have executed this Agreement.

Throughout the term of this Agreement all participants shall be represented by the SSDC for purposes of negotiating state supplemental rebates for prescribed drugs with drug manufacturers for their state Medicaid programs. Three caveats to this general rule apply. First, for the purpose of negotiating supplemental rebates defined as value-based agreements, Member States have the option to be represented by the SSDC, have representation outside of the SSDC or have some agreements represented by the SSDC and others outside of the SSDC. Value-based purchasing agreements shall have the same definition as Value-Based Purchasing arrangements as defined in 42 CFR § 447.502. Second, Member States have the option to, but need not be represented by the SSDC for the purposes of negotiating rebates with manufacturers on products other than prescribed drugs, including but not necessarily limited to diabetic supplies. For the purpose of this Agreement, prescribed drugs shall have the same definition as in 42 CFR §440.120. Third, if a manufacturer refuses to offer agreements to the SSDC, Member States can enter into supplemental rebate agreements for high-cost gene therapy drugs, and/or chimeric antigen receptor T-cell (CAR-T) drugs.

The continued purpose of the SSDC shall be to provide oversight for the Member States’

Medicaid purchasing pool. The continued focus of the pool related to product utilization in the Medicaid programs of the Member States shall be on negotiating and acquiring rebates supplemental to federal Medicaid rebates from drug manufacturers for drugs and negotiating and acquiring rebates from manufacturers of other products. The SSDC assures that each State retains the ability to individually manage its pharmacy benefit, customizing its own Preferred Drug List and Prior Approval programs.

The SSDC shall also provide a forum and/or vehicle for Member States to cooperate in other areas of pharmacy benefit administration and management in Medicaid and other publicly funded health benefit programs.

November 14, 2024. Page 3

II. Duration

This Agreement replaces the Consortium Agreement that ends on December 31, 2024. This

Agreement is scheduled to end December 31, 2025. The duration of the Agreement assures agreement for the term of the whole of the rebate calendar year to which SSDC contractual and operational activities apply. Any change in duration must be in writing and shall be executed upon a two-thirds vote of all Member States of the SSDC.

III. SSDC Responsibilities

A. The SSDC shall organize its work and activities to become an efficient and effective mechanism for negotiating Medicaid rebates on behalf of Member States, using their pooled covered lives.

B. The SSDC shall be able to add non-Medicaid populations to the pool upon approval from the Centers for Medicare and Medicaid Services.

C. The SSDC shall assure that the control of any purchasing pool is retained by the Member

States and not by any vendor contracting with the SSDC or its individual members.

D. The SSDC shall consider opportunities for cost savings in benefit areas other than drug purchases.

E. The SSDC shall provide a vehicle to exchange information, share ideas and plans, and promote association and coordination in matters pertaining to pharmacy benefit administration and management in publicly funded programs.

F. For purpose of financing itself, the SSDC shall be funded by payments by the Member

States.

G. For purposes of organizing and governing itself, the SSDC shall decide items by a two-thirds vote of all Member States of the SSDC. Items subject to a two-thirds vote include, but are not limited to, the following:

1. A logo to identify the collaborative group called the SSDC. This shall be available for use on stationery, business cards, display at meetings and presentations, or other purposes as agreed upon by the Member States.

2. State membership and participation.

3. An Agent State or States acting for all Member States, which shall have a term as determined by the Member States. At the direction of the Member States, the Agent State or States shall execute any contract for services needed by the SSDC.

Contracts include but may not be limited to the following:

a. Providing Medicaid supplemental drug rebate and other Medicaid pharmacy benefit rebate collective services on behalf of the SSDC and

b. Supporting SSDC activities.

4. A brief annual business plan and schedule of meetings and activities to assist the Member States to establish collective purchasing strategies and long term plans.

5. A base location, at a minimum for purposes of establishing a mailing address.

November 14, 2024. Page 4

H. For operational and procedural purposes, the SSDC shall decide items by a majority vote of all Member States of the SSDC. Items subject to a majority vote include but are not limited to the following:

1. The day and time of meetings.

2. The place or alternative method of meetings; that is, at the base location or elsewhere or by web meeting, telephone, written vote, or some other method.

3. The content and format of the SSDC web page.

4. The content and format of administrative reports.

I. Other actions taken by the SSDC shall be authorized by a two-thirds vote of the Member

States unless otherwise specified in this Agreement.

J. The SSDC may establish working committees charged with operational and procedural responsibilities related to its multi-state collaborative. The responsibilities of the working committees may include, but are not limited to:

1. Reviewing and approving SSDC contract procurement proposals;

2. Sharing information on the operations of any SSDC contract(s);

3. Reviewing and approving contract deliverables;

4. Meeting with contract vendor management, as needed, to assure resolution of issues and problems;

5. Meeting with contract vendor management, as needed, for long-range planning;

6. Sharing information related to contract vendor billings;

7. To the extent possible, establishing consistent policies among states; and

8. Referring issues for formal full SSDC action.

K. The SSDC shall assure Member States that they retain full control over administrating their individual benefit programs including but not limited to their Preferred Drug Lists and Prior Approval programs.

L. The SSDC shall assure Member States that they retain full control over administrating their individual benefit programs with their state resources or contractual relationships with Pharmacy Point of Sale, Pharmacy & Therapeutic Committee/Preferred Drug List (PDL), and/or Prior Authorization vendors.

IV. SSDC Rebate Collective Services

A. The SSDC shall secure a contract vendor to provide the following collective rebate related services:

1. Member States’ utilization data compilation: Compilation of Member States’ drug and drug product utilization data for Member State information and use, for presentation to manufacturers as part of the annual bid procurement, and for use in bid presentation and evaluation.

2. Rebate bid solicitation for annual review and as needed: Creation of a bid solicitation process including the provision of the vehicle(s) for manufacturers to submit bids. Communication with manufacturers throughout the process including but not limited to the web posting of general requests for proposals, November 14, 2024. Page 5 manufacturer specific requests for proposals, and responses to manufacturers’ questions.

3. Bid presentation at the SSDC annual meeting and as needed: Provision for Member State review of a compilation of offered bids with any pertinent related conditions, factors, and/or information.

4. Rebate bid negotiation annually and as needed: Negotiation that may occur at the request of a Member State or States after bid review.

5. Bid selection notification: Notification to manufacturers.

6. General collective administrative functions: Including but not limited to the creation and maintenance of a web page to provide manufacturers and others with pertinent information about the SSDC; general communications with participating states, manufacturers, and others; notification to manufacturers of changes in Member State participation during any agreement year(s); data development, analysis and reporting; data compilation and distribution; manufacturer participation tracking; drug representation tracking; and meeting organization, coordination, support, and management.

B. The rebate collective services shall be used by all Member States and the selected contract vendor shall support all Member States equally regardless of any other contractual relationship the contract vendor may have with an individual Member State.

In the event that there appears to be a conflict of interest that cannot be resolved, the matter shall be determined by two-thirds vote of the Member States.

C. A vendor contract was executed in 2019 by Vermont, acting as an Agent State of the

SSDC, with Change Healthcare Pharmacy Solutions. Vermont’s entity responsible for this contract is the Department of Vermont Health Access (hereinafter called “DVHA”).

The terms and conditions of the contract were determined by two-thirds vote of the then Member States. The current contract began April 1, 2019, and will continue through March 31, 2025. The contract may be extended for up to two additional one-year extensions upon mutual agreement by both parties. Details regarding the cost of rebate collective services are set forth in the 2019 contract and its amendments. A copy of this contract and any amendments is available on DVHA’s website:

https://dvha.vermont.gov/administration/grants-and-contracts/contracts.

D. The contract vendor for rebate collective services may charge accretion fees upon incorporating a new Member State into the operations of the SSDC. The Member State shall be responsible for reimbursing DVHA for both the cost of its accretion fee in addition to its share of the cost of rebate collective services

1. The accretion fee may be billed by the contract vendor upon the satisfactory completion of incorporation as deemed by the new Member State.

2. DVHA shall pay the contract vendor according to the terms of the approved contract.

E. The new Member State must pay DVHA for any accretion fee due. DVHA shall bill the new Member State for this fee.

1. DVHA may invoice the new Member State upon execution of this Agreement, or upon receipt of the rebate collective services vendor’s bill for the new Member State’s accretion fee.

https://dvha.vermont.gov/administration/grants-and-contracts/contracts

November 14, 2024. Page 6

2. The new Member State shall pay DVHA no later than sixty (60) days after the receipt of a bill from DVHA.

F. The payment for rebate collective services shall be managed by DVHA.

1. The cost of rebate collective services may be billed by the contract vendor in monthly increments against each month in the vendor contract year. The term “contract year” is defined as the twelve-month period in which services for a rebate calendar year are performed.

G. Each member State shall share equally in the cost of rebate collective services. DVHA shall bill the Member States or their agents quarterly an amount representing the contract costs for the previous three months. Member States or their agents shall pay DVHA or, at DVHA’s direction, the rebate services vendor for the rebate collective services no later than sixty (60) days after the receipt of a bill from DVHA.

H. Adjustments to costs for rebate collective services may occur. The handling of these adjustments shall be managed as determined by the membership.

V. SSDC Support Services

A. The SSDC shall secure a contract vendor to provide the following support services:

1. The Contractor shall be responsible for providing all resources necessary to deliver the services required by this contract in a timely fashion or according to the SSDC’s rebate calendar. The SSDC reserves the right to require the Contractor replace staff or subcontractors that are found to be unsuitable in a time-frame acceptable to the SSDC.

2. Support for the maintenance/development, review, and execution of the SSDC’s Memorandum of Understanding (MOU) including annual renewals.

3. Oversight of the SSDC rebate core collective services contract, and any other contracts that the SSDC Member States may collectively request during the term of the agreement, including:

a. Incorporation and coordination of Member State requested services in any executed SSDC contract.

b. Assistance with the development of any Request for Proposals for any contract replacement that may occur.

c. Assistance with any related re-procurement activities that may take place.

4. Assistance to states in the development of SSDC specific individual Medicaid State Plan

Amendments (SPAs) including any CMS negotiations.

5. Management activities in support of the SSDC including but not limited to:

a. State recruitment as directed by Member States, when contacted by states, as identified by SSDC contractor(s), as identified by the contractors of the Member States, or as otherwise identified.

b. Public information and relations for anyone interested in the SSDC, including those representing state legislative interests, non-Medicaid state agency representatives interested in the approach, and manufacturers. General public information documents available at the onset of the contract will be maintained; new materials will be developed as identified as necessary and as reviewed and approved by Member States. All materials

November 14, 2024. Page 7 must be available for general distribution and for posting on the SSDC web page managed by Change Healthcare.

c. Federal policy research, analysis, and reporting.

d. State operations research, analysis, and reporting.

e. Data analysis and reporting.

f. Other related needs as identified as necessary and reviewed and approved by Member

States.

6. Administrative activities in support of the SSDC including but not limited to:

a. Meeting (including Zoom/Teams meetings) management and coordination including identifying and/or responding to the need for meetings; developing agendas; scheduling times and places; distributing materials; etc.

b. Coordination of telephone and mailing services as needed.

c. Other related needs as identified as necessary and reviewed and approved by Member

States.

Select services as described may be provided solely to individual Member States. Other support services shall be used by all Member States. Generally, the selected vendor shall support all Member States equally.

B. In the course of the execution of support services, the selected contract vendor may have access to or knowledge of information belonging to the SSDC or its Member States. The selected contract vendor shall understand and agree that any and all information belonging to the SSDC, or its Member States shall be considered solely the property of the SSDC or its Member States and shall not be disclosed at any time to anyone outside the SSDC without the express permission of the affected Member State(s).

C. The payment for support services shall be managed by DVHA.

1. The cost of support services may be billed by the contract vendor in monthly increments against each calendar month.

D. Member States will share equally in the cost of all support services.

E. The Member States must pay DVHA representing Vermont as the Agent State of the

SSDC for support services received. DVHA shall bill the Member States or their agents for these services.

1. Billing and payment(s) shall be conducted in a time and manner agreeable to

DVHA and the individual Member States.

2. A Member State or its agent shall pay DVHA or, at DVHA’s direction, the SSDC

Support Services vendor, no later than sixty (60) days after the receipt of a bill from DVHA.

F. Adjustments to costs for support services may occur. The handling of these adjustments shall be managed as determined by the membership.

November 14, 2024. Page 8

VI. SSDC Other Services

A. Other services may be required by the SSDC as determined by the membership.

B. Costs for services approved by the membership shall be shared by the Member States as determined by the membership.

C. Adjustments to costs for other services may occur. The handling of these adjustments shall be managed as determined by the membership.

VII. Individual Member State Responsibilities

A. Each Member State shall appoint a Designated Official to represent that Member State in the work and meetings of the SSDC. Each Member State may change the person identified as a Designated Official at its convenience and may supplement the SSDC effort by the commitment and contribution of additional resources to assist the Designated Official in any manner it chooses.

1. The Designated Official of each Member State casts the State’s vote in the SSDC.

2. Designated Officials and their assistants, if any, shall be the key points of contact between the day-to-day activities of the respective Member State and the work of the SSDC.

3. Designated Officials shall provide leadership and guidance to encourage and promote the success of the SSDC as a multi-state collaborative.

B. Each Member State shall submit a Medicaid State Plan Amendment including a drug

Supplemental Rebate Agreement to the Centers for Medicare and Medicaid Services (CMS) in support of and as related to its participation in the SSDC.

C. Each Member State shall use the SSDC and its designated contract vendor for the rebate collective services listed above in IV.A except that individual Member States may also negotiate value-based agreements or high-cost cell and gene therapies outside of the SSDC and its designated contract vendor.

D. Each Member State may use the SSDC support services vendor for the support services listed in V.A.

E. Each Member State may have access to or knowledge of information belonging to the

SSDC or its other Member States. Each Member State shall understand and agree that any and all information belonging to the SSDC or its other Member States shall be considered solely the property of the SSDC or its other Member States and shall not be disclosed at any time to anyone outside the SSDC without the express permission of the affected Member State(s).

F. Each Member State shall commit to paying its individual costs under the SSDC and its share of collective services and other services costs under the terms described above in IV.C. through L.; V.D. through H.; and VI.B. and C.

G. Each Member State shall commit to timely payment of its costs.

November 14, 2024. Page 9

H. Each Member State shall commit to providing information necessary to support the activities of the SSDC including but not necessarily limited to:

1. Drug utilization data by NDC, cost, number of prescriptions and units.

2. Product utilization data by identifier, cost, number of prescriptions and units.

3. Lists of drugs and products requiring Prior Authorizations and the drug and product specific approval criteria.

4. This section shall not apply to disclosure of drug utilization data based on value-based agreements negotiated by an individual Member State.

I. Each Member State shall agree to share with the other Member States relevant documents, designs, plans, proposals, contracts and other reports developed in connection with its participation in the SSDC and other benefit administration or management methods, systems, or contracts to work towards the goals set forth herein.

VIII. Equitable Billing Adjustments and Repayment Term

A. The Member States agree to allow DVHA an “Administrative Discount” of $10,000, to be deducted from its annual costs under this Agreement, to reflect its annual administrative investment in the SSDC’s operation. This discount shall be funded in equal shares by the other Member States.

B. The Member States agree to share equally the risk of financial loss resulting from a Member State’s failure to reimburse DVHA for shared costs as required under sections IV, V, or VI.

C. If the SSDC finds that a Member State or its agent or former Member State or its agent has not paid any portion of its shared costs pursuant to sections IV, V, or VI, or the Risk Sharing payments authorized by the SSDC under this section more than 180 days after the date of billing, the SSDC shall:

1. Certify the unpaid costs as a “Delinquent” payment; and

2. Consider the Member State or former Member State to be a “Delinquent

State,” meaning the state is not in good standing.

D. SSDC shall meet within 90 days of certifying a Delinquent payment to approve a “Risk Sharing “payment which shall be billed by DVHA to all Member States in good standing.

1. The amount of the Risk Sharing payment shall be the amount of the certified Delinquent payment divided by the number of Member States in good standing (to include the State of Vermont). The SSDC may agree to an alternative apportionment by unanimous vote of the Member States in good standing.

2. The SSDC shall authorize DVHA to bill the Member States in good standing for the Risk Sharing payment immediately and all such payments shall be due within 60 days of the billing date.

E. The SSDC may determine, by a vote of its Member States in good standing, that a

Delinquent State shall be suspended from participation in the activities of the SSDC and receipt of services under this Agreement.

November 14, 2024. Page 10

1. Suspension will end at such time as the SSDC restores the Delinquent State’s good standing.

2. Members who are suspended shall be notified of their liability for services rendered but not yet billed at the time of suspension, which shall be equitably calculated by the SSDC.

F. The SSDC shall restore the good standing of a Delinquent State if the Delinquent State pays DVHA the Delinquent payment and is current on all other payments due under this Agreement.

G. DVHA may assess and refund Risk Sharing payments and apply the Administrative Discount as follows:

1. DVHA may apply the Administrative Discount approved in this section to reduce its own share of costs under this Agreement by up to $10,000 per calendar year.

2. DVHA may increase the proportion of costs billed to the other Member States or their agents in equal shares to fund the Administrative Discount.

3. DVHA may increase the amounts billed to all Member States in good standing or their agents to include Risk Sharing payments approved under this section.

4. DVHA shall decrease the amount billed to a Member State or their agents in an amount equal to the Member State’s Risk Sharing payment upon receipt of the respective portion of a Delinquent payment.

H. Upon receipt of a Delinquent payment from a Delinquent State, the SSDC may authorize

DVHA to provide a cash refund of a related Risk Sharing payment made by or on behalf of a Member State or former Member State. The SSDC may also reimburse a Member State for Risk Sharing Payments in cash at its sole discretion in a manner adopted by vote of the SSDC, except that under no circumstances shall DVHA be required to refund the cash reimbursement for Risk Sharing payments except through funds received through satisfaction of a corresponding Delinquent payment.

IX. General Terms and Conditions

A. Sovereign Immunity: No Member State waives its sovereign immunity by entering into this Agreement. Each State individually retains all immunities and defenses provided by law with respect to any action based or occurring as a result of this Agreement.

B. Third Party Benefits: The Member States do not intend to benefit any third party, and this Agreement shall not be construed to confer any such benefits.

C. Individual Right to Terminate: Notwithstanding anything in this Agreement to the contrary, any one of the Member States may terminate its participation in this Agreement without cause at any time before April 1 or after the Annual Meeting by submitting a written resignation to all other Member States or to the Support Services vendor (which shall immediately inform all other Member States). However, a Member State that terminates after April 1 year shall be responsible for its share of costs for the entire term of the then-current Consortium Agreement (i.e., through December 31).

November 14, 2024. Page 11

D. Interpretation: This Agreement shall be construed to affect each Member State in accordance with the laws of each Member’s State and is binding upon and inures to the benefit of the Member States and their respective successors and assigns.

E. State Systems: Participation in this Agreement does not obligate any one of the Member

States to implement or modify any benefit administration or management method, system, or contract developed jointly or individually by the Member States. Each Member State shall retain the right to implement, modify or terminate any method, system, or contract pertaining to benefit administration or management which it decides is appropriate to that State’s interests.

F. Annual Review: The terms and conditions of this Agreement shall be reviewed annually and as needed.

G. Confidentiality: Member States shall protect the confidentiality of information shared pursuant to this agreement as permitted or required by law. Member states shall ensure that written agreements with agents or contractors engaging in activities under this agreement prohibit the disclosure or use of confidential or proprietary information obtained through such activities except as required to support the Member State’s participation in the SSDC or as required by law.

X. Amendments

Any amendment to this Agreement must be reduced to writing and ratified by two-thirds vote of the

SSDC.

Sovereign States Drug Consortium

November 14, 2024. Page 12

SOVEREIGN STATES DRUG CONSORTIUM (SSDC)

2025 CONSORTIUM AGREEMENT

Signature Page

Wherefor, in consideration of the mutual agreements made herein among the member states of the SSDC, the undersigned have hereunto set their hands in their official capacity only, and without personal liability.

This Agreement is effective January 1, 2025, and is scheduled to end December 31, 2025. Its terms and conditions apply to rebate calendar year 2025.

State:

Signature:

Printed Name:

Title:

Date:

State:

Signature:

Printed Name:

Title:

Date:

North Dakota

Abigail Dschaak

State Procurement Officer

12/18/2024

Sara Stolt Deputy Commissioner

12/19/2024

ND Department of Health and Human Services https://adobecancelledaccountschannel.na2.documents.adobe.com/verifier?tx=CBJCHBCAABAAcvpgG-ZD8hOtPr7voOAvm6l3W8Z4Ltyu

SSDC Consortium Agreement 2025_FNAL -signed Final Audit Report 2024-12-19

Created: 2024-12-18

By: Kyle Nelson (kylnelson@nd.gov)

Status: Signed

Transaction ID: CBJCHBCAABAAcvpgG-ZD8hOtPr7voOAvm6l3W8Z4Ltyu

"SSDC Consortium Agreement 2025_FNAL - signed" History Document created by Kyle Nelson (kylnelson@nd.gov) 2024-12-18 - 10:16:24 PM GMT- IP address: 165.234.252.245

Document emailed to Sara Stolt (sarastolt@nd.gov) for signature

2024-12-18 - 10:18:31 PM GMT

Email viewed by Sara Stolt (sarastolt@nd.gov) 2024-12-19 - 2:25:07 PM GMT- IP address: 104.47.64.254

Document e-signed by Sara Stolt (sarastolt@nd.gov) Signature Date: 2024-12-19 - 2:25:51 PM GMT - Time Source: server- IP address: 165.234.252.245

Agreement completed.

2024-12-19 - 2:25:51 PM GMT